Last reviewed · How we verify

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

BioMarin Pharmaceutical · Phase 3 active Small molecule

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is a Small molecule drug developed by BioMarin Pharmaceutical. It is currently in Phase 3 development.

At a glance

Generic namesapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin
SponsorBioMarin Pharmaceutical
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

What is sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin?

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is a Small molecule drug developed by BioMarin Pharmaceutical.

Who makes sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin?

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is developed by BioMarin Pharmaceutical (see full BioMarin Pharmaceutical pipeline at /company/biomarin-pharmaceutical).

What development phase is sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin in?

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is in Phase 3.

Related